Articles

Videos

Podcasts

Clinical

Despite significant advances in cancer treatment, molecular sequencing and enrollment of Black patients in clinical trials are still less than that of White and Asian patients.

NCI Acting Director: Equitable Precision Medicine Requires Concerted Implementation Efforts

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA Approves Bevacizumab Biosimilar for Six Types of Cancer

Researchers at the European Society for Medical Oncology Congress presented findings that show osimertinib may clinically reduce the risk of lung cancer recurrence.

Osimertinib Significantly Improves Disease-Free Survival in EGFR-Mutated Lung Cancer 

Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.

Trastuzumab Deruxtecan Shows Clinically Meaningful Response in Non-Small Cell Lung Cancer

An estimated 31.4% of individuals with non-squamous non–small cell lung cancer treated with the combination were alive at 3 years compared to 17.3% for those on chemotherapy alone.

Limited Course of Tremelimumab, Imfinzi Combination Sustained Overall Survival Improvements in Non-Squamous Non–Small Cell Lung Cancer

Data presented at the 2022 ESMO congress show poziotinib has high activity in both treatment-naïve and previously treated patients with non-small cell lung cancer.

Study Finds High Activity With Poziotinib in Non-Small Cell Lung Cancer with HER2 Exon 20 Insertion Mutations

Data presented at the European Society for Medical Oncology Congress showed that sotorasib increased progression-free survival to 1 year in 25% of patients with KRAS G12C-mutated non-small cell lung cancer. 

Sotorasib Significantly Improves Progression-Free Survival for KRAS G12C-Mutated Non-Small Cell Lung Cancer in Phase 3 Trial

Sunvozertinib is an oral, potent EGFR exon20ins inhibitor with wild-type EGFR selectivity.

Sunvozertinib Meets Primary Endpoint in First Pivotal Study in Platinum-Pretreated NSCLC With EGFR Mutations

But the 2021 modifications to the US Preventive Services Task Force recommendations do not eliminate the inequalities, analysis shows.

 Study Results Link Lung Cancer Screening Guideline Changes to Racial Disparity Reductions

Disease management is moving toward holistic care of the patient in the long term.

Great Strides Drive Progress Toward Precision Medicine in Lung Cancer Therapy

® Lung Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that begins on the lungs, including non-small cell lung cancer and small cell lung cancer.